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A {#sec1}
=

Adenovirus infections, inflammation due to, 701--702

Airway

 collapse of, hypoxic episodes in, 831--833

 immaturity of, hypoxic episodes and, 831--833

Airway disease, in BPD, **857--870**

 evaluation of, 862--863

 intubation and extubation problems in, 858

 outcomes of, 860--862

 subglottic stenosis, 863--865

 tracheomalacia and tracheobronchomalacia, 865

 tracheotomy placement for, 865--868

Airway smooth muscle cells, 689--690

Alveolar cells, ontogeny of, 688--689

Alveolar stage, of lung development, 686--687

Amino acids, intravenous, 800

Angiogenesis, hypoxic episodes and, 833

Angiogenic growth factors, as biomarkers, 745, 747

Angiopoietin/Tie-2 ligand/receptor system, as biomarker, 745

Anterior cricoid split, for subglottic stenosis, 864

Aortopexy, 865

Apnea of prematurity, **825--838,** 860

Assist/control ventilation, 791

Asthma, inflammation due to, 703--704

AT1 and AT2 cells, 688--689

Atelectrauma, in mechanical ventilation, 783

Atopy, inflammation due to, 703--704, 707

Azithromycin

 clinical trials of, 773

 evidence-based recommendations for, 756--761

 for *Ureaplasma* colonization, 727--732

B {#sec2}
=

Balloon dilation, for subglottic stenosis, 864

Barotrauma

 in mechanical ventilation, 783

 inflammation due to, 701

Benefits of Oxygen Saturation Targeting (BOOST) trial, 812--818, 830

Biofilms, in *Ureaplasma* colonization, 720--721

Biofluid biomarkers, for BPD, 744--747

Biomarkers, for BPD, **739--754**

 biofluid, 744--747

 clinical predictors, 741--742

 exhaled breath, 747

 genomic, 747--748

 imaging, 742--744

 lung function, 744

 need for, 740

 respiratory microbiome, 748--749

 types of, 741

Biotrauma, in mechanical ventilation, 783--784

Blood tests, 744--746

Bone morphogenetic proteins, as biomarkers, 745

BOOST (Benefits of Oxygen Saturation Targeting) trial, 812--818, 830

BPD. *See* Bronchopulmonary dysplasia.

Breath biomarkers, for BPD, 747

BREATH database, 691

Bronchoalveolar lavage fluid, biomarkers in, 746--747

Bronchoalveolar stem cells, 688--690

Bronchopulmonary dysplasia

 airway disease in, **857--870**

 biomarkers of, **739--754**

 causes of, 925

 definition of, 739

 diagnosis of, **739--754**

 early predictors of, **739--754**

 epidemiology of, 755--756

 etiology of, 783

 growth failure with, 799

 hypoxic episodes in, **825--838**

 imaging for, **871--887**

 immunology and, **697--718**

 mechanical ventilation for. *See* Mechanical ventilation.

 molecular biology of, **685--695**

 natural history of, **911--931**

 nutrition impact on, **797--806**

 old versus new, 782

 oxygen saturation monitoring in, **807--823**

 pathogenesis of, 890

 phenotypes of, 924

 prematurity effects on, **697--718**

 prevention of, **755--779,** 799--800, 924--925

 prognosis for, 740

 pulmonary hypertension in. *See* Pulmonary vascular disease and pulmonary hypertension.

 treatment of

 airway disease and, **857--870**

 mesenchymal stem cells for, 689--690, 773, **889--910**

 nutritional status and, 800

 postdischarge, 801, 861--862

  *Ureaplasma* colonization in, **719--738**

Bronchoscopy, 863

Bronchospasm, hypoxic episodes in, 831--833

Budesonide, clinical trials of, 773

C {#sec3}
=

Caffeine

 clinical trials of, 773

 evidence-based recommendations for, 756, 758--759, 761--764

Calfactant, clinical trials of, 773

Canadian Oxygen Trial (COT), 813--818

Canalicular stage, of lung development, 686

Cardiac catheterization, in pulmonary vascular disease, 842, 845--847

Cardiac defects, BPD in, 846--847

Cartilage graft, for subglottic stenosis, 864

Chemical mediators, 699

Chemokines, as biomarkers, 746

Chemosensitivity, peripheral, 828--829

Chest radiography, 872--873

 as biomarker, 742--743

Childhood Origins of Asthma (COAST) Project, 707

CHIME (Collaborative Home Infant Monitoring Evaluation), 830

Chorioamnionitis, 699--701

 biomarkers of, 745

 hypoxic episodes and, 827--828

  *Ureaplasma,* 719--738

Chronic lung disease of prematurity. *See also* Bronchopulmonary dysplasia.

 postnatal infections and, **697--718**

Clara cells, 745, 773

Clarithromycin, for *Ureaplasma* colonization, 727--732

Clinical predictors, as BPD biomarkers, 741--742

COAST (Childhood Origins of Asthma) Project, 707

Collaborative Home Infant Monitoring Evaluation (CHIME), 830

Colonization, or microbiota, alterations of, 708

Colorimetric assays, for *Ureaplasma,* 727--728

Computed tomography, 743, 873--876, 923

Connective tissue-type mast cells, 692

Continuous positive air pressure (CPAP)

 nasal, 858--859

 trials of, 782

 use of, 786--787

Continuous transcutaneous oxygen tension monitoring, 811--812

Cor pulmonale, 842

Coronavirus infections, inflammation due to, 702--704

COT (Canadian Oxygen Trial), 813--818

CPAP. *See* Continuous positive air pressure (CPAP).

Culture, *Ureaplasma,* 726--727

Cytokines

 as biomarkers, 745--746

 hypoxic episodes and, 827--828

Cytomegalovirus infections, inflammation due to, 702--703

Cytosolic DNA sensors, in *Ureaplasma* colonization, 721

D {#sec4}
=

Deoxyhemoglobin, in oximetry, 808

Dexamethasone, evidence-based recommendations for, 756, 759, 761, 765--769, 772

Diffusing capacity of lung carbon monoxide, 915--916, 919

Diuretics, 800

DNA chip assay, for *Ureaplasma,* 729

DNA methylation analysis, 690--691, 925

Double aortic arch, 865

Down syndrome, subglottic stenosis in, 863

Dynamic compliance (Cdyn), 914

E {#sec5}
=

Echocardiography

 as biomarker, 744

 for pulmonary vascular disease, 842--844, 846

ELGAN (Extremely Low Gestational age Newborns) Study, 700, 798

Emphysema

 computed tomography for, 875

 nuclear medicine for, 876

Endoscopic surgery, for subglottic stenosis, 864

Endothelial injury, in lung, 841

Endothelial monocyte activating factor, as biomarker, 745, 747

End-tidal carbon monoxide test, as biomarker, 744

Enterovirus infctions, inflammation due to, 702

EPICure study, 921--922

Epithelial cells

 biomarkers derived from, 745

 ontogeny of, 688--689

Erythromycin, for *Ureaplasma* colonization, 730--732

Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, 742, 798

Exercise tolerance, 924

Exhaled breath biomarkers, for BPD, 747

Expiratory microbiome biomarkers, for BPD, 748--749

Extremely Low Gestational age Newborns (ELGAN) Study, 700, 798

F {#sec6}
=

Fetal-neonatal transition, hypoxic episodes and, 828--829

Fibrotic markers, 745

Fluid intake, 800

Forced expiratory flow (FEF), 913--914, 916, 921--922

Forced vital capacity (FVC), 916

Functional residual capacity (FRC), 913--915, 918

G {#sec7}
=

Gastroesophageal reflux, subglottic stenosis and, 864

Genetic factors, 704, 925

Genome-wide association studies, of biomarkers, 748

Genome-wide transcriptional assays, 691--692

Genomic analysis, integrated, in lung development, 690--691

Genomic biomarkers, for BPD, 747--748

Glutathione peroxidase, as biomarker, 746

GRADE (Grading of Recommendations, Assessment, Development, Evaluation) framework, 756--757

Growth

 hypoxic episodes and, 831

 nutrition and, 798--799

H {#sec8}
=

Healthy lung, definition of, 924

High-flow nasal cannula, 859--860

High-frequency ventilation and variations, 789--791

Hippo/Yap pathway, 689

Home care, for BPD, 860--861

Hydrocortisone, clinical trials of, 773

Hydrogen peroxide, toxicity of, 810

8-Hydroxydeoxyguanosine, as biomarker, 747

Hydroxyl radical, toxicity of, 810

Hypercapnia

 bronchoconstriction in, 833

 permissible, in ventilation, 791

Hyper-polarized magnetic resonance imaging, 880--882

Hypertension, pulmonary. *See* Pulmonary vascular disease and pulmonary hypertension.

Hypokalemia, 800

Hyponatremia, 800

Hypoxia, lung development arrest in, 891--892

Hypoxic episodes, **825--838**

 animal models of, 826--827

 causes of, 826--829

 consequences of, 829--831

 immature airway role in, 831--833

 pulmonary vasoconstriction role in, 833--834

Hypoxic injury, in mechanical ventilation, 785--786

I {#sec9}
=

Ibuprofen, clinical trials of, 773

Imaging, **871--887**

 chest radiography, 872--873

 computed tomography, 873--876

 magnetic resonance imaging, 876--882

 nuclear medicine, 876--882

Imaging biomarkers, 742--744

Immunoglobulin A protease, as *Ureaplasma* virulence factor, 721

Immunomodulatory properties, of stem cell therapy, 900

Infections

 epidemiology of, 697--698

 hypoxic episodes in, 827--828

 pathogenesis of, 698--699

 postnatal, 701--704

 prenatal, 697--701

 susceptibility to, 704--708

 timing of, 706--708

Inflammation

 biomarkers of, 745

 hypoxic episodes in, 827--828

 in *Ureaplasma* colonization, 722

 postnatal induction of, 701--704

 prenatal induction of, 697--701

 susceptibility to, 704--708

Inositol

 as nutritional supplement, 802--803

 clinical trials of, 773

INSURE (intubation-surfactant-extubation) approach, 787

Interferons, deficiency of, 707

Interleukins

 as biomarkers, 745--746

 defects of, inflammation due to, 704----705

Intermittent hypoxic episodes, **825--838**

Intrauterine growth, restriction of, 798

Intubation and extubation problems, 858, 865--866

Intubation-surfactant-extubation (INSURE) approach, 787

K {#sec10}
=

Kim predictive model, 742

L {#sec11}
=

Laryngeal cleft, 865

Laryngoscopy, 863--864

Leukotrienes, as biomarkers, 747

Lipids, intravenous, 800

Lipopolysaccharides, hypoxic episodes and, 827--828

Long-chain polyunsaturated fatty acids, as nutritional supplement, 803

Lung clearance index (LCI), 914, 919

Lung compliance, as biomarker, 744

Lung development

 arrested, 841, 890--892

 biology of, **685--695**

Lung function biomarkers, for BPD, 744

LUNG Molecular Atlas Program, 691

Lung resistance, as biomarker, 744

Lymphocytes, alterations of, lung disease in, 705--707

M {#sec12}
=

Macrolides. *See also specific agents.*

 for *Ureaplasma* colonization, 727--732

Magnetic resonance imaging, 743, 876--882

Mast cell biomarkers, 748

Matrix metalloproteinase, as biomarker, 745

Mechanical ventilation, **791--796**

 critical time in (first hour), 784--785

 guidelines for, 791--792

 history of, 781--782

 inflammation due to, 701

 lung-protective strategies of, 787--791

 mitigating, 784--787

 tracheotomy for, 867

 ventilator-associated lung injury in, 783--786

 versus noninvasive support, 786--787

Medical home, 801, 860--861

Mesenchymal stromal (stem) cells, 689--690, **889--910**

 arrested lung development and, 890--892

 clinical trials of, 773

 disrupted vascular development and, 892--895

 disruption of, 890

 fibrosis and, 895--896

 inflammation and, 895--896

 long-term effects of, 896--897

 manufacture of, 904--905

 mechanism of action of, 897--900

 overview of, 890

 oxidative stress and, 895--896

 sources of, 893, 902--903

 treatment with

 administration of, 901--903

 arrested lung development and, 891

 efficacy of, 900--905

 for fibrosis, 896, 895--896

 for inflammation, 896, 895--896

 for oxidative stress, 896, 895--896

 for pulmonary hypertension, 895

 safety of, 905--906

Metapneumovirus infections, inflammation due to, 702

Microarray analysis, 691--692

Microbiota, colonization of, alterations of, 708

microRNAs, as biomarkers, 748

MIRna Dynamic Regulatory Events Miner, 690--691

Molecular assays, for *Ureaplasma,* 727--728

Molecular biology, of bronchopulmonary dysplasia, **685--695**

Monocyte chemoattractant proteins, as biomarkers, 746

Montelukast, clinical trials of, 773

Multiple banded antigen, as *Ureaplasma* virulence factor, 721

N {#sec13}
=

Nasal cannula, high-flow, 859--860

Nasal CPAP, 858--859

Nasal intermittent positive pressure ventilation, 786--787

Natural history, of BPD, **911--931**

 clinical pulmonary outcomes and, 922--923

 exercise evolution and, 924

 imaging changes and, 923

 pulmonary function testing for, 912--922

 research priorities for, 925, 927

Neonatal Oxygenation Prospective Meta-Analysis (NeOProM) collaboration, 813

Neonatal Research Network, 782

Neonatal Resuscitation Program and International Liaison Committee on Resuscitation guidelines, 785

NeOProM (Neonatal Oxygenation Prospective Meta-Analysis) collaboration, 813

Neutrophil-gelatinase-associated lipocalin, as biomarker, 746

Nitric oxide, inhaled

 clinical trials of, 773

 for pulmonary vascular disease, 849

Nod-like receptors, in *Ureaplasma* colonization, 721

Nuclear medicine, 876--882

Nutrition, **797--806**

 growth and, 798--799

 research opportunities in, 801--803

O {#sec14}
=

Open lung strategy, for ventilation, 789--790

Oxidant biomarkers, 746

Oxidative stress, hypoxic episodes and, 829--831

Oximetry

 clinical trials of, 812--818

 history of, 811--812

 principles of, 808--809

Oxygen

 toxicity of, 809--811

 transport of, 809

Oxygen free radicals, 810--811

Oxygen saturation, **807--823**

 deficient, episodes of, **825--838**

 in pulmonary vascular disease, 847--848

 monitoring of

 clinical trials of, 812--818

 history of, 811--812

 principles of, 808--809

Oxygen therapy, inflammation due to, 701

Oxyhemoglobin, in oximetry, 808

P {#sec15}
=

Paracrine effect, of stem cell therapy, 899--900

Parainfluenza virus infections, inflammation due to, 702--703

Passage number, in stem cell preparation, 904--905

Peripheral chemosensitivity, 828--829

Pharmacotherapy, **755--779**. *See also individual agents.*

Phospholipases, as *Ureaplasma* virulence factors, 721

Placenta, infections of, 699--701

Pneumonia, inflammation due to, 701

Polymerase chain reaction, for *Ureaplasma,* 727--729

Polyunsaturated fatty acids, as biomarkers, 747

Positive end-expiratory pressure, 785, 789, 791

Predictive models, 741--742

Prematurity, chronic lung disease of. *See* Bronchopulmonary dysplasia.

Pressure-controlled ventilation, 787--788

Preterm birth, in *Ureaplasma* colonization, 722

PreVILIG (Prevention of Ventilator Induced Lung Injury Group) database, 742

Proactant alfa, clinical trials of, 773

Protein, intravenous, 801

Pseudoglandular stage, of lung development, 686

Pulmonary function tests

 as biomarkers, 744

 computed tomography compared with, 875

 for natural history studies, 912--922

Pulmonary vascular disease and pulmonary hypertension, **839--855**

 biomarkers of, 745--746

 diagnosis of, 744, 842--845

 epidemiology of, 842--845

 mesenchymal stem cells for, 892--895

 pathogenesis of, 840--842

 risk factors for, 845--846

 treatment of, 847--850

Pulmonary vascular resistance, 841--842, 846--847

Pulmonary vasoconstriction, in hypoxic episodes, 833--834

R {#sec16}
=

Radiography, 742--743, 872--873, 923

RANTES, as biomarker, 745

Reactive osygen species, biomarkers of, 746

Resistance (Rrs), 913--914

Respiratory compliance (Crs), 913--914

Respiratory decompensation, gradual, 861--862

Respiratory failure, acute, 861

Respiratory failure scorer, 742

Respiratory microbiome, as biomarker, 748--749

Respiratory syncytial virus infections, inflammation due to, 701--704

Retinopathy of prematurity, 811--812, 830--831

Rhinovirus infections, inflammation due to, 702

Right ventricular myocardial performance index, 842

RIG-like receptors, in *Ureaplasma* colonization, 721

Rubella, inflammation due to, 702

S {#sec17}
=

Saccular stage, of lung development, 686

Scintigraphy, 876--882

Sepsis

 biomarkers of, 745

 inflammation due to, 701

Serine/threonine kinase, as *Ureaplasma* virulence factor, 721

Serine/threonine protein phosphatase, as *Ureaplasma* virulence factor, 721

Sildenafil, for pulmonary vascular disease, 849

Single-photon emission computed tomography, 876

Smell prints, as biomarkers, 747

SPOCK2 gene, 748, 925

Stem cells. *See* Mesenchymal stromal (stem) cells.

STOP-ROP (Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity) trial, 812--813

Stromal cells. *See* Mesenchymal stromal (stem) cells.

Subglottic stenosis, 863--865

Superoxide dismutase, as biomarker, 746

Superoxide radical, toxicity of, 810

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP) trial, 812--813

SUPPORT (Surfactant, Positive Pressure, and Oxygenation Randomized Trial), 781--782, 813--818, 830

Surfactant and surfactant proteins

 administration of, 787

 clinical trials of, 773

 in *Ureaplasma* colonization, 721--722

Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT), 781--782, 813--818, 830

Sustained technique, for ventilation, 785

Synchronized intermittent mandatory ventilation, 791

T {#sec18}
=

T cells, alterations of, lung disease in, 705--707

Toll-like receptors, in *Ureaplasma* colonization, 721--722

Total lung capacity (TLC), 915

Trachea, vascular compression of, 865

Tracheal aspirate, biomarkers in, 746--747

Tracheotomy placement, 865--868

Transcriptomics, **685--695**

Transforming growth factor, as biomarker, 745

Transplantation, of stem cells, 905

Tryptase, as biomarker, 748

Tumor necrosis factor-α, as biomarker, 746

Tumor necrosis factor-β, as biomarker, 745

U {#sec19}
=

United Kingdom Oscillation Study, 791

*Ureaplasma,* colonization of, **719--738**

 animal studies of, 725--726

 biomarkers of, 745

 bronchopulmonary dysplasia associations with, 723--724

 diagnosis of, 726--729

 epidemiology of, 722--726

 eradication of, 727, 730--732

 host response to, 721--722

 infant characterization in, 722--723

 species involved in, 720--722

 virulence factors in, 721

Urine, biomarkers in, 747

V {#sec20}
=

Vascular bed, hypoplastic, 892

Vascular endothelial growth factor, as biomarker, 745, 747

Vascular remodeling, 833

Vasodilators, for pulmonary vascular disease, 848--849

Ventilation. *See* Mechanical ventilation.

Ventilation/perfusion scans, 876--882

Viral infections, inflammation due to, 701--702

Vitamin A

 clinical trials of, 773, 799--802

 evidence-based recommendations for, 756, 759, 761, 770--774

Vitamin D

 clinical trials of, 773

 effects of, 802--803

Volatile organic compounds, as biomarkers, 747

Volume-targeted ventilation, 787--788

Volutrauma, in mechanical ventilation, 783

W {#sec21}
=

Weaning, from respiratory support, 858--859, 861--862

Wheezing, inflammation due to, 703--704, 707

X {#sec22}
=

Xanthine oxidase, 811
